Chapter Five

Hematology Collaboration and Licensing Partnering Analysis Report 2024 with Directory of Deals Signed Since 2016 - ResearchAndMarkets.com

Retrieved on: 
金曜日, 5月 3, 2024
Biotechnology, Pharmaceutical, Health, Chapter Six, Directory, Chapter Three, Hyperlink, Chapter One, Chapter, Chapter Five, Orientation, Confidentiality, A-Z, Chapter Four, Intellectual property

Hematology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hematology deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Hematology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hematology deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of hematology deals from 2016 to 2024.
  • Chapter 3 covers the financial deal terms for deals signed in the hematology field with stage of development announced.
  • Chapter 5 provides a comprehensive and detailed review of hematology deals signed and announced since 2016 where a contract document is available.

Infectious Diseases Collaboration and Licensing Agreements Analysis Report 2024 with Directory of 1,726 Deals Signed Since 2019 - ResearchAndMarkets.com

Retrieved on: 
月曜日, 4月 29, 2024
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Chapter Six, Directory, Chapter Three, Infection, Hyperlink, Chapter One, Chapter, Chapter Five, Orientation, A-Z, Chapter Four, Pharmaceutical industry

Infectious Diseases Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious diseases deals entered into by the world's leading biopharma companies.

Key Points: 
  • Infectious Diseases Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious diseases deals entered into by the world's leading biopharma companies.
  • Fully revised and updated, the report provides details of 1726 infectious disease deals from 2019 to 2024.
  • Chapter 5 provides a comprehensive and detailed review of infectious diseases deals signed and announced since 2019 where a contract document is available.
  • Infectious Diseases Collaboration and Licensing Deals includes:
    In Infectious Diseases Collaboration and Licensing Deals, the available deals are listed by:

Oncology Collaboration and Licensing Agreements Analysis Report 2024 with Directory of 3685 Deals Signed Since 2019 - ResearchAndMarkets.com

Retrieved on: 
水曜日, 4月 24, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Chapter Three, Hyperlink, Chapter One, Chapter Five, Orientation, Chapter Four, Chapter Six, A-Z, Directory, Chapter, Nursing

Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the oncology deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the oncology deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of 3685 oncology deals from 2019 to 2024.
  • Chapter 5 provides a comprehensive and detailed review of oncology deals signed and announced since 2019 where a contract document is available.
  • Oncology Collaboration and Licensing Deals includes:
    In Oncology Collaboration and Licensing Deals, the available deals are listed by:

Zero Energy Devices Markets and Technology Report 2024-2044: Essential Guide to this Large New ZED Opportunity - How to Create a $1 Billion ZED Business - ResearchAndMarkets.com

Retrieved on: 
火曜日, 4月 23, 2024
Technology, Other Technology, Conclusion, Internet, Executive, Chapter Six, RFID, SWOT, Chapter Ten, Chapter Three, Heart, Communication, Electricity, Ultra, Research, Transducer, EAS, Life, Rest, Imperial College London, Attention, Electronics, Chapter Seven, Wireless, WPT, Vibration, Chapter Nine, RIS, ZED, Movement, Toxicity, Chapter Five, Chapter Two, Telecommunications, IOT, Chapter Eight, Recycling, Chapter Four

The "Zero Energy Devices ZED: Self-Powered and Backscatter-Powered Electronics and Electrics Markets, Technology 2024-2044" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Zero Energy Devices ZED: Self-Powered and Backscatter-Powered Electronics and Electrics Markets, Technology 2024-2044" report has been added to ResearchAndMarkets.com's offering.
  • You can create a billion-dollar business from making the next ZED materials or devices as detailed in this commercially-oriented 408-page report.
  • The primary author has created several successful high-tech businesses, so the report is realistic, including warnings concerning dead ends and over-promising.
  • At this stage you will realise that many zero energy devices without storage have been presented throughout the report.

EQS-News: NOTICE TO CONVENE MULTITUDE SE’S ANNUAL GENERAL MEETING OF SHAREHOLDERS

Retrieved on: 
水曜日, 4月 10, 2024
Appendix, Letter, Exercise, EEST, The Annual Report, Audit committee, Annual, Audit, Annual general meeting, Remuneration, Report, Register, Person, PwC, Proxy, Book, Annual report, Chapter Five, Auditor, EUR, Chapter Ten, Frankfurt Stock Exchange, Notice, Address, KHT, Mass meeting, Treasury, ID, Malta Business Registry, Security (finance)

The Board of Directors proposes to the Annual General Meeting that, for the financial year 2023, a dividend of EUR 0.19 per share be distributed.

Key Points: 
  • The Board of Directors proposes to the Annual General Meeting that, for the financial year 2023, a dividend of EUR 0.19 per share be distributed.
  • Shareholders, who are registered in the shareholders’ register of the Company, and who wish to participate in the General Meeting, must register for the meeting by giving prior notice of participation as instructed below.
  • Shareholders may participate in the General Meeting of Shareholders and exercise their rights at the meeting by way of proxy representation.
  • On the date of this notice to the Annual General Meeting of Shareholders, dated 28 March 2024, the total number of shares in Multitude SE is 21,723,960 and each of these shares carries one vote.

Notice of Annual General Meeting (AGM) of Bioretec Ltd

Retrieved on: 
金曜日, 4月 5, 2024
Remuneration, Charter, Annual, EUR, Chair, PwC, Nomination, Exercise, Communication, Address, Travel, Mass meeting, Shareholder, Bank statement, Investment company, Annual general meeting, Tax, Companies Act, Chapter Five, Privacy, EET, Holding company

TAMPERE, Finland, April 5, 2024 /PRNewswire/ -- The shareholders of Bioretec Ltd are hereby invited to the Annual General Meeting to be held on 26 April 2024 at 10:00 a.m. (Finnish time) at Bioretec premises in the auditorium of Tampark, at the address Yrittäjänkulma 5, FI-33710 Tampere, Finland.

Key Points: 
  • A shareholder may participate in the Annual General Meeting and exercise their rights at the meeting by way of proxy representation.
  • The authorization is valid until the end of the next Annual General Meeting, however, no longer than until 30 June 2025.
  • The Board of Directors proposes that the Annual General Meeting resolve to establish a shareholders' nomination board ("Nomination Board"), responsible for annually preparing and presenting to the Annual General Meeting and, if necessary, to an Extraordinary General Meeting, proposals on the composition (number of the members of the Board of Directors and the nominees) and remuneration of the Board of Directors.
  • The meeting minutes of the Annual General Meeting will be available on the company's website no later than 10 May 2024.

Notice of Annual General Meeting (AGM) of Bioretec Ltd

Retrieved on: 
金曜日, 4月 5, 2024
Remuneration, Charter, Annual, EUR, Chair, PwC, Nomination, Exercise, Communication, Address, Travel, Mass meeting, Shareholder, Bank statement, Investment company, Annual general meeting, Tax, Companies Act, Chapter Five, Privacy, EET, Holding company

TAMPERE, Finland, April 5, 2024 /PRNewswire/ -- The shareholders of Bioretec Ltd are hereby invited to the Annual General Meeting to be held on 26 April 2024 at 10:00 a.m. (Finnish time) at Bioretec premises in the auditorium of Tampark, at the address Yrittäjänkulma 5, FI-33710 Tampere, Finland.

Key Points: 
  • A shareholder may participate in the Annual General Meeting and exercise their rights at the meeting by way of proxy representation.
  • The authorization is valid until the end of the next Annual General Meeting, however, no longer than until 30 June 2025.
  • The Board of Directors proposes that the Annual General Meeting resolve to establish a shareholders' nomination board ("Nomination Board"), responsible for annually preparing and presenting to the Annual General Meeting and, if necessary, to an Extraordinary General Meeting, proposals on the composition (number of the members of the Board of Directors and the nominees) and remuneration of the Board of Directors.
  • The meeting minutes of the Annual General Meeting will be available on the company's website no later than 10 May 2024.

Analysis of Joint Venture Deals in Pharmaceuticals and Biotechnology Between 2016-2024 - ResearchAndMarkets.com

Retrieved on: 
月曜日, 4月 1, 2024
Biotechnology, Pharmaceutical, Health, Chapter Three, Chapter Four, Chapter, Chapter One, A-Z, Orientation, Chapter Five, Chapter Six, Directory

The "Joint Venture Deals in Pharmaceuticals and Biotechnology 2016-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Joint Venture Deals in Pharmaceuticals and Biotechnology 2016-2024" report has been added to ResearchAndMarkets.com's offering.
  • Joint Venture Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter joint venture deals.
  • Fully revised and updated, the report provides details of joint venture deals from 2016 to 2024.
  • Joint Venture Deals in Pharmaceuticals and Biotechnology includes:
    In Joint Venture Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

Distribution Deal Trends in Diagnostics Report 2024 with Analysis of Deals Signed Since 2016 - ResearchAndMarkets.com

Retrieved on: 
金曜日, 3月 29, 2024
Professional Services, Health, Other Professional Services, Legal, Other Health, Pharmaceutical, Biotechnology, Chapter Four, Chapter Three, Chapter Five, Orientation, Chapter, Chapter One, Directory, A-Z, Publishing

The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to ResearchAndMarkets.com's offering.
  • Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution deals.
  • Fully revised and updated, the report provides details of distribution deals from 2016 to 2024.
  • Distribution Deals in Diagnostics provides the reader with the following key benefits:
    Directory of deals by company A-Z, therapy focus and technology type
    Distribution Deals in Diagnostics includes:
    In Distribution Deals in Diagnostics, the available deals are listed by:

Global Biotechnology Licensing Agreements Analysis Report 2024 with Directory of Deals Signed Since 2019 - ResearchAndMarkets.com

Retrieved on: 
金曜日, 3月 29, 2024
Health, Biotechnology, Directory, Chapter Three, Chapter Four, Chapter, Chapter One, Confidentiality, A-Z, Orientation, Chapter Five, Chapter Six

Licensing Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter licensing deals.

Key Points: 
  • Licensing Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter licensing deals.
  • Fully revised and updated, the report provides details of licensing deals from 2019 to 2024.
  • The deal directory includes a comprehensive listing of all licensing deals announced since 2019.
  • Directory of deals by company A-Z, therapy focus and technology type
    Licensing Deals in Biotechnology includes:
    Analyzing contract agreements allows due diligence of:
    What are the rights granted or optioned?